PDS Biotechnology (NASDAQ:PDSB - Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect PDS Biotechnology to post earnings of ($0.29) per share for the quarter. Parties interested in participating in the company's conference call can do so using this link.
PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the company earned ($0.37) EPS. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
PDS Biotechnology Stock Up 1.5 %
Shares of PDS Biotechnology stock traded up $0.05 during midday trading on Thursday, hitting $3.28. The company's stock had a trading volume of 336,442 shares, compared to its average volume of 606,417. PDS Biotechnology has a 1-year low of $2.53 and a 1-year high of $6.85. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $120.77 million, a P/E ratio of -2.69 and a beta of 1.93. The stock has a 50-day simple moving average of $3.25 and a 200-day simple moving average of $3.28.
Wall Street Analyst Weigh In
Several research firms have weighed in on PDSB. Alliance Global Partners raised PDS Biotechnology to a "strong-buy" rating in a research note on Wednesday, August 21st. HC Wainwright restated a "buy" rating and set a $21.00 price target on shares of PDS Biotechnology in a report on Thursday, October 24th. Finally, StockNews.com upgraded shares of PDS Biotechnology from a "sell" rating to a "hold" rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $14.25.
Check Out Our Latest Research Report on PDS Biotechnology
About PDS Biotechnology
(
Get Free Report)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Featured Stories
Before you consider PDS Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDS Biotechnology wasn't on the list.
While PDS Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
